Skip to content
DataLookout
Menu

M.D. Anderson Cancer Center clinical trial pipeline

Get alerts when M.D. Anderson Cancer Center's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19

What changed in the last 30 days

52 trials changed in the last 30 days: 5 stopped, 30 with notable changes, 17 with minor changes only.

  1. Stopped: AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix Trial terminated M.D. Anderson Cancer CenterPhase 2 NCT05063916
  2. Stopped: OCRA Distress & Unmet Needs Trial status changed: Not Yet Recruiting → Suspended M.D. Anderson Cancer CenterNot applicable NCT07591623
  3. Minor: Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy Enrollment closed, study ongoing M.D. Anderson Cancer CenterPhase 2/3 NCT05431595
  4. Stopped: Tocilizumab, Ipilimumab, and Nivolumab · Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Trial terminated M.D. Anderson Cancer CenterPhase 2 NCT04940299
  5. Notable: Active Surveillance and Chemotherapy Before Surgery · Stage II-III Rectal Cancer Primary and study completion pushed from Oct 31, 2026 to Oct 31, 2028 M.D. Anderson Cancer CenterEarly Phase 1 NCT03594630
  6. Notable: HSV G207 · Recurrent or Refractory Cerebellar Brain Tumors Primary and study completion dates pushed to Dec 31, 2027 M.D. Anderson Cancer CenterPhase 1 NCT03911388
  7. Notable: Mobile Phone Text-based Intervention to Reduce Sedentary Behavior and Engage Communities on the Importance of Healthy Lifestyles: the TEXT2MOVE Study Primary and study completion pushed from Oct 31, 2026 to Oct 31, 2028 M.D. Anderson Cancer CenterNot applicable NCT05217108
  8. Notable: Neuromodulation as a Treatment for Chemotherapy-Induced Peripheral Neuropathy Primary and study completion pushed from Oct 1, 2026 to Oct 1, 2028 M.D. Anderson Cancer CenterNot applicable NCT02573766
  9. Notable: Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery Enrollment reopened M.D. Anderson Cancer CenterPhase 3 NCT03214510
  10. Notable: Zanzalintinib Plus Cemiplimab · BRAF Wild-Type Anaplastic Thyroid Cancer Recruitment opened M.D. Anderson Cancer CenterPhase 2 NCT07470489
  11. Notable: TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers Recruitment opened M.D. Anderson Cancer CenterPhase 1 NCT07553390
  12. Notable: Dissemination Of Lung Cancer Screening Education Through Tobacco Quitlines Recruitment opened M.D. Anderson Cancer CenterNot applicable NCT07720141
  13. Notable: Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies Primary and study completion pushed from Oct 31, 2026 to Oct 31, 2028 M.D. Anderson Cancer CenterNot specified NCT05011045
  14. Notable: Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas Primary and study completion pushed from Aug 31, 2026 to Aug 31, 2028 M.D. Anderson Cancer CenterNot applicable NCT05676450
  15. Notable: TROP2 CAR/IL-15 TGFBR2 KO NK Cell · Oral Premalignant Lesions Recruitment opened M.D. Anderson Cancer CenterPhase 1 NCT07631013
  16. Notable: Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab · Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC) Primary and study completion pushed from Nov 1, 2026 to Nov 1, 2028 M.D. Anderson Cancer CenterPhase 2 NCT05681039
  17. Notable: Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies Enrollment reopened M.D. Anderson Cancer CenterPhase 2 NCT06444880
  18. Notable: Subcutaneous Blinatumomab · Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia Trial status changed: Suspended → Active, Not Recruiting M.D. Anderson Cancer CenterPhase 2 NCT07192237
  19. Notable: PLM-102 · Relapsed And Refractory Acute Myeloid Leukemia Recruitment opened M.D. Anderson Cancer CenterPhase 1 NCT07549464
  20. Minor: Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma Enrollment closed, study ongoing M.D. Anderson Cancer CenterPhase 2 NCT06053658
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-11-18 NCT07944079 Acupuncture Delivery In The Clinical Decision Unit (CDU) For The Management Of Pain… Not Yet Recruiting
2026-11-18 NCT07944105 SPARK UPS/MFS: Study Of BET Inhibition With ZEN003694 To Potentiate Anti-Tumor Responses… Phase 1/2 Not Yet Recruiting
2026-11-16 NCT07938073 Phase 2 Study Of IDH 1/2 Inhibitor Vorasidenib In Patients With IDH2-Mutated Intrahepatic… Phase 2 Not Yet Recruiting
2026-11-05 NCT07917832 Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin… Phase 2 Not Yet Recruiting
2026-11-03 NCT07911618 Data Collection For Patients With Sickle Cell Disease Not Yet Recruiting
2026-10-28 NCT07899801 A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small… Phase 1 Not Yet Recruiting

Active trials by phase

Early Phase 1
27
Phase 1
129
Phase 1/2
94
Phase 2
350
Phase 2/3
12
Phase 3
25
Phase 4
8
Not charted: 417 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials, top 10 of 56

Get alerts when M.D. Anderson Cancer Center's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free